Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IVAX Insider Trading -- Ignore unavailable to you. Want to Upgrade?

To: 5,17,37,5,101,... who wrote (293)	12/17/1997 4:25:00 PM
From: flickerful	Respond to of 756

<<<<<<<<<<I get the feeling that Ivax's proprietary drug efforts are a fabrication. Management doesn't give any information as to what they are working on, if anything.>>>>>>>>>>>> IT IS A JOKE.

To: 5,17,37,5,101,... who wrote (293)	12/17/1997 4:32:00 PM
From: flickerful	Respond to of 756

sorry about the link; recap is almost as flaky as IVAX. i connect sometimes to links, and other times i receive bizarre dead-ends... jackson, could you tell me how the completion of the "verapamil" line could be of any consolation when we know zip about verapamil, or any other of their so-called "lines". there is something insidious going on here, and i do NOT like it at all.

To: 5,17,37,5,101,... who wrote (293)	12/17/1997 4:59:00 PM
From: flickerful	Respond to of 756

here's another $0.00: Wednesday December 17, 9:30 am Eastern Time Ivax gets FDA OK for 120-mg verapamil dose MIAMI, Dec 17 (Reuters) - IVAX Corp said Wednesday the U.S. Food and Drug Administration had approved an Abbreviated New Drug Application for its generic pharmaceutical product called verapamil HCl ER in 120-mg tablets. Verapamil is used to manage hypertension and is the generic equivalent of Knoll Pharmaceutical Co's Isoptin SR and G.D. Searle & Co's Calan SR. Knoll is a division of Germany's BASF (BASF.F), and Searle is a unit of Monsanto Co (NYSE:MTC - news). Ivax said its Zenith Goldline Pharmaceuticals Inc unit will market the product. Zenith Goldline now has authority to make and market all three dosage strengths of verapamil extended-release tablets, Ivax said. ------------------------------------------------------------------------